Vladimir J.N. Bykov

7.2k citations

66 papers · 5.5k indexed · 2 hit papers · h-index 32

Oncology top 0.5%
- Cancer-related Molecular Pathways 35
Biotechnology top 0.5%
- Cancer Research and Treatments 9
Cancer Research top 1%
Molecular Biology top 2%
- Ubiquitin and proteasome pathways 14
- Epigenetics and DNA Methylation 11
- DNA Repair Mechanisms 7
- RNA modifications and cancer 6
- Cell death mechanisms and regulation 5
Hematology top 2%
Dermatology
- Skin Protection and Aging 11

Co-authors: Klas G. Wiman Galina Selivanova Jan Bergman Sofi Eriksson Julie Bianchi Natalia Issaeva Monica Hultcrantz Jérémy Lambert
Cited by: Oncology Biotechnology Cancer Research
Partner nations: Sweden Russia France

In The Last Decade

Vladimir J.N. Bykov

66 papers receiving 5.4k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2017 Targeting mutant p53 for efficient cancer therapy
2002 Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Peers

Countries citing papers authored by Vladimir J.N. Bykov

Since Specialization

Citations

This map shows the geographic impact of Vladimir J.N. Bykov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vladimir J.N. Bykov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vladimir J.N. Bykov more than expected).

Fields of papers citing papers by Vladimir J.N. Bykov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vladimir J.N. Bykov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vladimir J.N. Bykov. The network helps show where Vladimir J.N. Bykov may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Vladimir J.N. Bykov, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vladimir J.N. Bykov Line = papers co-authored together Vladimir J.N. Bykov links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (RB1) gene Mireia Palomar-Siles,Viktor Yurevych,Vladimir J.N. Bykov,Klas G. Wiman	2023	4
2	Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN Angelos Heldin,Matko Čančer,Mireia Palomar-Siles,Susanne Öhlin,Meiqiongzi Zhang,Alexander Sun-Zhang,Anna Mariani,Jianping Liu,Vladimir J.N. Bykov,Klas G. Wiman	2023	7
3	Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine Mireia Palomar-Siles,Angelos Heldin,Meiqiongzi Zhang,Charlotte Strandgren,Viktor Yurevych,Jip T. van Dinter,Sem A.G. Engels,Damon A. Hofman,Susanne Öhlin,Birthe Meineke,Vladimir J.N. Bykov,Sebastiaan van Heesch,Klas G. Wiman	2022	16
4	Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells Sophia Ceder,Sofi Eriksson,Ying Liang,Emarndeena H. Cheteh,Si Min Zhang,Kenji M. Fujihara,Julie Bianchi,Vladimir J.N. Bykov,Lars Abrahmsén,Nicholas J. Clemons,P. Nordlund,Sean G. Rudd,Klas G. Wiman	2021	12
5	A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death Sophia Ceder,Sofi Eriksson,Emarndeena H. Cheteh,Swati Dawar,Mariana Corrales Benitez,Vladimir J.N. Bykov,Kenji M. Fujihara,Mélodie Grandin,Xiaodun Li,Susanne Ramm,Corina Behrenbruch,Kaylene J. Simpson,Frédéric Hollande,Lars Abrahmsén,Nicholas J. Clemons,Klas G. Wiman	2020	29
6	Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246 Lena Haffo,Jun Lu,Vladimir J.N. Bykov,Sebastin Santosh Martin,Xiaoyuan Ren,Lucia Coppo,Klas G. Wiman,Arne Holmgren	2018	55
7	APR-246 reactivates mutant p53 by targeting cysteines 124 and 277 Qiang Zhang,Vladimir J.N. Bykov,Klas G. Wiman,Joanna Zawacka‐Pankau	2018	186
8	The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells Naoise C. Synnott,Stephen F. Madden,Vladimir J.N. Bykov,John Crown,Klas G. Wiman,Michael J. Duffy	2018	27
9	Role of Thiol Reactivity for Targeting Mutant p53 Qiang Zhang,Jan Bergman,Klas G. Wiman,Vladimir J.N. Bykov	2018	17
10	Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy Vladimir J.N. Bykov,Qiang Zhang,Meiqiongzi Zhang,Sophia Ceder,Lars Abrahmsén,Klas G. Wiman	2016	101
11	Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis Jérémy Lambert,Ali Moshfegh,Pierre Hainaut,Klas G. Wiman,Vladimir J.N. Bykov	2009	85
12	PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain Jérémy Lambert,Petr Gorzov,Dmitry B. Veprintsev,Maja Söderqvist,Dan Segerbäck,Jan Bergman,Alan R. Fersht,Pierre Hainaut,Klas G. Wiman,Vladimir J.N. Bykov	2009	450
13	Mutant p53 targeting by the low molecular weight compound STIMA‐1 Nicole Zache,Jérémy Lambert,Nina Rökaeus,Jinfeng Shen,Pierre Hainaut,Jan Bergman,Klas G. Wiman,Vladimir J.N. Bykov	2008	95
14	Pregnancy health and outcome in two cities in the Kola Peninsula, Northwestern Russia Ljudmila Talykova,Arild Vaktskjold,Natalja Garissonovna Serebrjakova,Timofej Vladimirovitsj Khokhlov,Natalja Jurievna Strelkovskaja,Valery Chashchin,А Н Никанов,Jon Øyvind Odland,Vladimir J.N. Bykov,Evert Nieboer	2007	13
15	In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249 Huimin Shi,Jérémy Lambert,A. Hautefeuille,Vladimir J.N. Bykov,Klas G. Wiman,Pierre Hainaut,Claude Caron de Fromentel	2007	26
16	Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs Vladimir J.N. Bykov,Natalia Issaeva,Nicole Zache,Alexandre Shilov,Monica Hultcrantz,Jan Bergman,Galina Selivanova,Klas G. Wiman	2005	193
17	Novel cancer therapy by reactivation of the p53 apoptosis pathway Vladimir J.N. Bykov,Klas G. Wiman	2003	43
18	Small molecules that reactivate mutant p53 Vladimir J.N. Bykov,Galina Selivanova,Klas G. Wiman	2003	95
19	Effect of age on the formation and repair of UV photoproducts in human skin in situ Guogang Xu,Erna Snellman,Vladimir J.N. Bykov,Christer T. Jansén,Kari Hemminki	2000	45
20	Critical evaluation of medical, statistical, and occupational data sources in the Kola Peninsula of Russia pertinent to reproductive health studies Jon Øyvind Odland,Valeri Tchachtchine,Vladimir J.N. Bykov,P. E. Fiskebeck,Eiliv Lund,Yngvar Thomassen,Evert Nieboer	1999	29

About Vladimir J.N. Bykov

Vladimir J.N. Bykov is a scholar working on Oncology, Dermatology and Biotechnology, having authored 66 papers that have together received 5.5k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (35 papers), Ubiquitin and proteasome pathways (14 papers), Skin Protection and Aging (11 papers), Epigenetics and DNA Methylation (11 papers), Cancer Research and Treatments (9 papers), DNA Repair Mechanisms (7 papers), RNA modifications and cancer (6 papers) and Cell death mechanisms and regulation (5 papers). The work is most often cited by research in Oncology (3.1k citations), Biotechnology (787 citations) and Cancer Research (1.1k citations). Vladimir J.N. Bykov has collaborated with scholars based in Sweden, Russia and France. Frequent co-authors include Klas G. Wiman, Galina Selivanova, Jan Bergman, Sofi Eriksson, Julie Bianchi, Natalia Issaeva, Monica Hultcrantz, Jérémy Lambert, Peter M. Chumakov and Elena N. Pugacheva.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact